Pengaruh terapi dupilumab pada dermatitis atopik sedang hingga berat
Abstract
Abstrak
Dupilumab merupakan antibodi monoklonal yang bekerja spesifik sebagai antagonis reseptor-α IL-4 yang menghambat kedua pensinyalan IL-4 dan IL-13 pada reseptor IL-4. Dermatitis atopik merupakan kaskade inflamasi dimediasi Th2 yang memproduksi sitokin IL-4 dan IL-13. Inflamasi kronis kulit ini disertai dengan eksaserbasi dan remisi berulang dan ditandai lesi eksem yang pruritus, yang menganggu aktivitas serta kualitas tidur pasien di malam hari dan berakibat menurunnya kualitas hidup pasien. Tujuan: Untuk mengetahui pengaruh terapi dupilumab pada dermatitis atopik sedang hingga berat; Metode: Artikel ini disusun berdasarkan review beberapa literatur yang berhubungan dengan pengaruh terapi dupilumab terhadap pengobatan dermatitis atopik sedang hingga berat; Hasil: Pada penelusuran literatur didapatkan pengaruh terapi dupilumab terhadap pengobatan dermatitis atopik sedang hingga berat berupa perbaikan indeks skor keparahan lesi serta peningkatan kualitas hidup pasien dermatitis atopik sedang hingga berat; Kesimpulan: Terdapat pengaruh terapi dupilumab terhadap perbaikan indeks skor keparahan lesi dan peningkatan kualitas hidup pasien dermatitis atopik sedang hingga berat.
Kata kunci: Dupilumab; anti IL-4Rα; Dermatitis Atopik; Keparahan Lesi; Kualitas Hidup.
Keywords
Full Text:
PDFReferences
Peters N, Peters AT. Atopic dermatitis. Allergy Asthma Proc. 2019;40(6):433–6.
Awosika O, Kim L, Mazhar M, Rengifo-Pardo M, Ehrlich A. Profile of dupilumab and its potential in the treatment of inadequately controlled moderate-to-severe atopic dermatitis. Clinical, Cosmetic and Investigational Dermatology. 2018. p. 41–9.
Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nature Reviews Disease Primers. 2018. p. 1.
Nutten S. Atopic dermatitis: Global epidemiology and risk factors. Ann Nutr Metab. 2015;66(1):8–16.
Katayama I, Aihara M, Ohya Y, Saeki H, Shimojo N, Shoji S, et al. Japanese guidelines for atopic dermatitis 2017. Allergol Int [Internet]. 2017;66(2):230–47. Available from: http://dx.doi.org/10.1016/j.alit.2016.12.003
Tsianakas A, Ständer S. Dupilumab: A milestone in the treatment of atopic dermatitis. The Lancet. 2016. p. 1–2.
Gooderham MJ, Hong HC ho, Eshtiaghi P, Papp KA. Dupilumab: A review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;
Simpson EL. Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials. Dermatol Ther (Heidelb). 2017;7(2):243–8.
Cork MJ, Eckert L, Simpson EL, Armstrong A, Barbarot S, Puig L, et al. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J Dermatolog Treat. 2019;1–9.
Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and Safety of Dupilumab in Adolescents with Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatology. 2020;E1–13.
de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t. Br J Dermatol. 2018;178(5):1083–101.
Paller AS, Simpson EL, de Bruin-Weller M, Weisman J, Lockshin B, Hultsch T, et al. 621 Dupilumab in adolescents with moderate-to-severe atopic dermatitis and a history of inadequate response, or intolerance to cyclosporine: subgroup analysis from a pivotal 16-week trial. J Invest Dermatol. 2019;139:S106.
Paller AS, Siegfried EC, Thaçi D, Wollenberg A, Cork MJ, Arkwright PD, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;
Katoh N, Kataoka Y, Saeki H, Hide M, Kabashima K, Etoh T, et al. Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials. Br J Dermatol. 2020;183:39–51.
